LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

Search

Pacific Biosciences of California Inc

Chiusa

SettoreSettore sanitario

1.1 -0.9

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.09

Massimo

1.17

Metriche Chiave

By Trading Economics

Entrata

63M

2.4M

Vendite

-743K

39M

EPS

-0.2

Margine di Profitto

6.045

Dipendenti

575

EBITDA

18M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+94.64% upside

Dividendi

By Dow Jones

Utili prossimi

6 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

339M

Apertura precedente

2

Chiusura precedente

1.1

Notizie sul Sentiment di mercato

By Acuity

50%

50%

198 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Pacific Biosciences of California Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 mag 2025, 22:34 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 mag 2025, 23:48 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Technical Recovery -- Market Talk

12 mag 2025, 23:46 UTC

Discorsi di Mercato

Nikkei Likely to Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

12 mag 2025, 23:34 UTC

Discorsi di Mercato

Trade Deal Lowers US Recession Risks to 35% -- Market Talk

12 mag 2025, 23:21 UTC

Discorsi di Mercato

US-China Trade Deal Still Risks Stagflation; Supply Chain Disruption -- Market Talk

12 mag 2025, 22:54 UTC

Discorsi di Mercato

Australian Treasurer Warns Uncertainty Will Still Dominate Markets -- Market Talk

12 mag 2025, 22:43 UTC

Utili

Telefonica Brasil 1Q EPS BRL0.65 >VIV

12 mag 2025, 22:14 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mag 2025, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Ampol Expects Replacement-Cost Ebitda Uplift by Run Rate at End-2025 of Around A$30 Million/Year

12 mag 2025, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Ampol Expects Pretax Proceeds of Around A$65 Million From Transactions

12 mag 2025, 22:07 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell Australia Retail Electricity Business for Nominal Sum

12 mag 2025, 22:07 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell Australia Retail Electricity Business to AGL

12 mag 2025, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Meridian to Take on Flick, Z Energy Branded Electricity Customers

12 mag 2025, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Meridian Energy to Buy Business From Ampol for NZ$70 Million

12 mag 2025, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell New Zealand Electricity Retailing Businesses to Meridian Energy

12 mag 2025, 22:04 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 mag 2025, 21:15 UTC

Notizie principali

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- 2nd update -- WSJ

12 mag 2025, 21:01 UTC

Utili

Constellation Software 1Q Rev $2.65B >CSU.T

12 mag 2025, 21:01 UTC

Utili

Constellation Software 1Q Net $115M >CSU.T

12 mag 2025, 21:01 UTC

Utili

Constellation Software 1Q EPS $5.44 >CSU.T

12 mag 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

12 mag 2025, 20:50 UTC

Discorsi di Mercato
Utili

Basic Materials Roundup: Market Talk

12 mag 2025, 20:44 UTC

Notizie principali

Trade Thaw Sparks Stock Rally, Leaves Wall Street Cautious -- WSJ

12 mag 2025, 20:31 UTC

Notizie principali

How to Think About the Stock Market When Earnings Guidance Becomes Meaningless -- Heard on the Street -- UPDATED -- WSJ

12 mag 2025, 20:24 UTC

Utili

Energy Vault Holdings: Encouraging News on China/U.S. Tariff Pause, Pending Final Positive Resolution and Timing >NRGV

12 mag 2025, 20:24 UTC

Utili

Energy Vault Holdings: No Change to Current Guidance, With Potential Rev Upside on Accelerated U.S. Battery Deliveries in 2025 >NRGV

12 mag 2025, 20:24 UTC

Notizie principali

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- WSJ

12 mag 2025, 20:22 UTC

Acquisizioni, Fusioni, Takeovers

Spirit AeroSystems Holdings: IRS Rules That Sale to Boeing Will Qualify as a Reorganization Under Section 368(a)(1)(B)

12 mag 2025, 20:15 UTC

Utili

Rigetti Computing Reports Earnings. How the Company Takes a Different Approach to Quantum. -- Barrons.com

12 mag 2025, 20:10 UTC

Utili

Blink Charging 1Q Rev $20.8M >BLNK

Confronto tra pari

Modifica del prezzo

Pacific Biosciences of California Inc Previsione

Obiettivo di Prezzo

By TipRanks

94.64% in crescita

Previsioni per 12 mesi

Media 2.18 USD  94.64%

Alto 3 USD

Basso 1.5 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Pacific Biosciences of California Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

6

Acquista

5

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.13 / N/ASupporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

198 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.